Summary
Abbott Laboratories reported strong third-quarter 2020 results, driven significantly by its Diagnostics segment, which benefited from the company's rapid and broad rollout of COVID-19 testing solutions. Total sales increased by 9.6% to $8.85 billion, or 10.6% excluding foreign exchange, with the Diagnostics segment showing a substantial 38.2% increase. This growth in diagnostics, particularly from molecular and rapid tests, helped offset some of the pandemic-related slowdowns in the Medical Devices segment. The company maintained a robust financial position with increased cash reserves and managed its debt effectively.
Financial Highlights
51 data pointsBeta
Financial Statements
Beta
| Revenue | $8.85B |
| Cost of Revenue | $3.97B |
| Gross Profit | $4.89B |
| R&D Expenses | $580.00M |
| SG&A Expenses | $2.30B |
| Operating Expenses | $7.36B |
| Operating Income | $1.50B |
| Interest Expense | $137.00M |
| Net Income | $1.23B |
| EPS (Basic) | $0.69 |
| EPS (Diluted) | $0.69 |
| Shares Outstanding (Basic) | 1.77B |
| Shares Outstanding (Diluted) | 1.79B |
Key Highlights
- 1Total net sales increased by 9.6% to $8.85 billion in Q3 2020, with a 10.6% increase excluding foreign exchange.
- 2The Diagnostics segment saw significant growth of 38.2% (4.1% excluding foreign exchange) due to strong demand for COVID-19 diagnostic tests.
- 3Medical Devices segment sales grew 3.4% (2.6% excluding foreign exchange), with Diabetes Care showing strong double-digit growth, though other areas experienced COVID-19 related procedure volume declines.
- 4Established Pharmaceutical Products sales decreased by 9.3% (6.0% excluding foreign exchange), impacted by market dynamics in emerging markets and COVID-19.
- 5Nutritional Products segment sales increased by 2.6% (4.1% excluding foreign exchange), driven by both pediatric and adult nutritionals.
- 6Net earnings increased to $1.23 billion ($0.69 per diluted share) in Q3 2020, compared to $960 million ($0.53 per diluted share) in Q3 2019.
- 7The company's cash and cash equivalents increased to $4.48 billion as of September 30, 2020, up from $3.86 billion at the end of 2019, reflecting strong operating cash flow.
Frequently Asked Questions
The COVID-19 pandemic significantly boosted Abbott's Diagnostics segment due to the launch and widespread adoption of its COVID-19 testing products, including molecular, antibody, and antigen tests. While this drove overall sales growth, the pandemic also negatively impacted the Medical Devices segment, particularly in areas like cardiovascular and neuromodulation, due to reduced procedure volumes. The company also saw some impact on its pharmaceutical and nutritional businesses in certain markets.
The primary driver of sales growth was the Diagnostics segment, largely fueled by the rapid development and commercialization of Abbott's COVID-19 diagnostic tests. Increased demand for these tests on various platforms, including ID NOW, BinaxNOW, and its laboratory-based systems, contributed substantially to the segment's strong performance. Additionally, the Nutritional Products segment showed positive growth, and the Medical Devices segment saw contributions from Diabetes Care.
Abbott maintained a strong financial position, with cash and cash equivalents increasing to $4.48 billion as of September 30, 2020. The company generated substantial cash flow from operations, which helped fund its activities, including debt repayment and dividend payments. Abbott also has access to a $5 billion credit line, providing further liquidity if needed. The company has also been actively managing its debt, including issuing new notes and repaying maturing debt.
The Established Pharmaceutical Products segment experienced a sales decrease in the third quarter of 2020, impacted by market dynamics in key emerging markets and the broader effects of the COVID-19 pandemic. While specific growth drivers like China and other Asian/Latin American countries showed some resilience, overall demand was affected. Future performance will likely depend on the recovery of emerging markets and the company's ability to navigate ongoing market challenges.